Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LEO 130852A
- Development stage
- Unknown
- Lead developer
- LEO Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
LEO 130852A is a topically administered investigational agent being developed by LEO Pharma for the treatment of steroid-induced skin atrophy. The drug is currently in phase I clinical trials, where it is being evaluated for its ability to maintain skin thickness and reduce the atrophic effects caused by topical corticosteroid use. The precise mechanism of action has not been disclosed, but its development targets prevention or mitigation of skin thinning associated with prolonged steroid therapy.
Beyond the preview
Go deeper on LEO 130852A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LEO 130852A.